|
ARHGAP19 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
4.720400E-03 |
| Normal-vs-Stage3 |
2.37532216118552E-12 |
| Normal-vs-Stage4 |
2.44580000696715E-09 |
| Stage1-vs-Stage2 |
3.130000E-01 |
| Stage1-vs-Stage3 |
5.353800E-01 |
| Stage1-vs-Stage4 |
2.423200E-01 |
| Stage2-vs-Stage3 |
5.233600E-01 |
| Stage2-vs-Stage4 |
9.410100E-02 |
| Stage3-vs-Stage4 |
9.982000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.441500E-03 |
| Normal-vs-Asian |
3.98630000000288E-05 |
| Caucasian-vs-AfricanAmerican |
5.624000E-01 |
| Caucasian-vs-Asian |
8.105600E-01 |
| AfricanAmerican-vs-Asian |
5.401000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.28990160167086E-11 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.893500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.88837834258493E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
8.76470000021889E-07 |
| Normal-vs-Age(81-100Yrs) |
1.315820E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.192400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.147400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.670200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.184800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.641600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.029400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.463800E-01 |
| Classical-VS-Follicular |
4.08339999999896E-05 |
| Classical-VS-Other |
3.428800E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
9.384400E-02 |
| Tall-VS-Other |
6.183800E-01 |
| Tall-VS-Normal |
4.584000E-04 |
| Follicular-VS-Other |
6.653200E-01 |
| Follicular-VS-Normal |
6.823100E-03 |
| Other-VS-Normal |
1.818990E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.53570506206324E-11 |
| Normal-vs-N1 |
4.69399999980524E-07 |
| N0-vs-N1 |
3.037000E-01 |
|
|
